Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Reseña (Review)

Health care services use among long-term breast cancer survivors: a systematic review

  • Jansana, A.
  • Posso, M.
  • Guerrero, I.
  • Prados-Torres, A.
  • Del Cura, M.I.
  • Castells, X.
  • Sala, M.
Purpose: Long-term breast cancer survivors are women surviving at least 5 years after diagnosis. This systematic review aimed to summarize the main characteristics and patterns of healthcare service use (frequency of visits, health providers visited, and preventive care performed) among long-term breast cancer survivors. Methods: We used standard Cochrane Collaboration methods and searched the MEDLINE and EMBASE databases up to January 2018. We included English language observational studies reporting health service use among long-term cancer survivors. The quality of the studies was appraised through the ROBINS-I assessment tool. Two independent reviewers performed both the study quality assessment and the data extraction. Results: A total of 23 observational studies were included that reported data on health services use by long-term breast cancer survivors. Despite heterogeneity among studies, about half of them reported that breast cancer survivors visited a medical provider at least once a year, as recommended by breast cancer survival guidelines. Although survivors visited medical providers with the recommended frequency, a substantial number used specialist care instead of primary care during follow-up. The results showed underuse of the recommended annual mammogram. Conclusions: Long-term breast cancer survivors differ in their health services use with regard to the frequency of visits as well as the health providers seen. Our results indicate the need for active surveillance through primary care providers in coordination with specialized care. Implications for cancer survivors: This review could help to standardize the management of breast cancer survivors and decision-makers to adapt their guidelines and clinical protocols.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study

  • Jansana, A.
  • Del Cura, I.
  • Prados-Torres, A.
  • Sanz Cuesta, T.
  • Poblador-Plou, B.
  • Gimeno Miguel, A.
  • Lanzuela, M.
  • Ibañez, B.
  • Tamayo, I.
  • Moreno-Iribas, C.
  • Padilla-Ruiz, M.
  • Redondo, M.
  • Comas, M.
  • Domingo, L.
  • Díaz-Holgado, A.
  • Salamanca, F.J.
  • Castells, X.
  • Sala, M.
  • SURBCAN, group
INTRODUCTION: Breast cancer has become a chronic disease due to survival improvement and the need to monitor the side effects of treatment and the disease itself. The aim of the SURBCAN study is to describe comorbidity, healthcare services use and adherence to preventive recommendations in long-term breast cancer survivors and to compare them with those in women without this diagnosis in order to improve and adapt the care response to this group of survivors. METHODS AND ANALYSIS: Population-based retrospective cohort study using real-world data from cancer registries and linked electronic medical records in five Spanish regions. Long-term breast cancer survivors diagnosed between 2000 and 2006 will be identified and matched by age and administrative health area with women without this diagnosis. Sociodemographic and clinical variables including comorbidities and variables on the use of health services between 2012 and 2016 will be obtained from databases in primary and hospital care. Health services use will be assessed through the annual number of visits to primary care professionals and to specialists and through annual imaging and laboratory tests. Factors associated with healthcare utilisation and comorbidities will be analysed using multilevel logistic regression models. Recruitment started in December 2018. ETHICS AND DISSEMINATION: This study was approved by the Ethics Committee of Parc de Salut Mar. The results of the study will be published in a peer-reviewed journal and will be presented at national and international scientific conferences and at patient associations. TRIAL REGISTRATION NUMBER: This protocol is registered in Clinical Trials.gov (identifier: NCT03846999).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Factors associated with readmissions in women participating in screening programs and treated for breast cancer, A retrospective cohort study

  • Miret, Carme|||0000-0001-6154-3998
  • Domingo, Laia|||0000-0003-4420-0891
  • Louro, Javier|||0000-0002-2985-3301
  • Barata, Teresa
  • Baré i Mañas, Marisa|||0000-0001-8085-2833
  • Ferrer, Joana
  • Carmona-Garcia, M. Carmen|||0000-0002-4011-9474
  • Castells, Xavier|||0000-0002-2528-0382
  • Sala, Maria|||0000-0002-9955-8746
Background: We aimed to identify the risk factors associated with early, late and long-term readmissions in women diagnosed with breast cancer participating in screening programs. Methods: We performed a multicenter cohort study of 1055 women aged 50-69 years participating in Spanish screening programs, diagnosed with breast cancer between 2000 and 2009, and followed up to 2014. Readmission was defined as a hospital admission related to the disease and/or treatment complications, and was classified as early (< 30 days), late (30 days-1 year), or long-term readmission (.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Exploring the Role of Breast Density on Cancer Prognosis among Women Attending Population-Based Screening Programmes

  • Domingo, Laia|||0000-0003-4420-0891
  • Sala, Maria|||0000-0002-9955-8746
  • Louro, Javier|||0000-0002-2985-3301
  • Baré i Mañas, Marisa|||0000-0001-8085-2833
  • Barata, Teresa
  • Ferrer, Joana
  • Carmona-Garcia, M. Carmen|||0000-0002-4011-9474
  • Comas Serrano, Mercè|||0000-0003-1926-2740
  • Castells, Xavier|||0000-0002-2528-0382
Background. Our aim was to assess the role of breast density on breast cancer mortality and recurrences, considering patient and tumour characteristics and the treatments received among women attending population-based screening programmes. Methods. We conducted a retrospective cohort study among women aged 50-69 years attending population-based screening programmes, diagnosed with invasive breast cancer between 2000 and 2009, and followed up to 2014. Breast density was categorised as low density (≤25% dense tissue), intermediate density (25-50%), and high density (≥50%). Cox proportional hazards regression models were fitted to estimate the adjusted hazard ratios (aHR) and 95% confidence intervals (95% CI) for death and recurrences, adjusting by patient characteristics, mode of detection (screen-detected vs. interval cancer), and tumour features. Results. The percentage of deaths and recurrences was higher among women with intermediate- and high-density breasts than among women with low-density breasts (p=0.011 for death; p=0.037 for recurrences). Adjusted Cox proportional hazards regression models revealed that women with intermediate- and high-density breasts had a higher risk of death than women with low-density breasts, being statistically significant for intermediate densities (aHR = 2.19 [95% CI: 1.16-4.13], aHR = 1.44 [95% CI: 0.67-3.1], respectively). No association was found between breast density and recurrences. Conclusions. Breast density was associated with a higher risk of death, but not of recurrences, among women participating in breast cancer screening. These findings reinforce the need to improve screening sensitivity among women with dense breasts and to routinely assess breast density, not only for its role as a risk factor for breast cancer but also for its potential influence on cancer prognosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Readmissions and complications in breast ductal carcinoma in situ, A retrospective study comparing screen- and non-screen-detected patients

  • Politi, Julieta|||0000-0001-7315-034X
  • Sala, Maria|||0000-0002-9955-8746
  • Domingo, Laia|||0000-0003-4420-0891
  • Vernet-Tomas, Maria|||0000-0002-5575-2475
  • Román, Marta|||0000-0001-9076-8918
  • Macià Guilà, Francesc|||0000-0002-6090-5894
  • Castells, Xavier|||0000-0002-2528-0382
Population-wide mammographic screening programs aim to reduce breast cancer mortality. However, a broad view of the harms and benefits of these programs is necessary to favor informed decisions, especially in the earliest stages of the disease. Here, we compare the outcomes of patients diagnosed with breast ductal carcinoma in situ in participants and non-participants of a population-based mammographic screening program. A retrospective cohort study of all patients diagnosed with breast ductal carcinoma in situ between 2000 and 2010 within a single hospital. A total of 211 patients were included, and the median follow-up was 8.4 years. The effect of detection mode (screen-detected and non-screen-detected) on breast cancer recurrences, readmissions, and complications was evaluated through multivariate logistic regression analysis. In the majority of women, breast ductal carcinoma in situ was screen-detected (63.5%). Screen-detected breast ductal carcinoma in situ was smaller in size compared to those non-screen-detected (57.53% < 20 mm versus 78.03%, p = 0.002). Overall, breast-conserving surgery was the most frequent surgery (86.26%); however, mastectomy was higher in non-screen-detected breast ductal carcinoma in situ (20.78% versus 9.7%, p = 0.024). Readmissions for mastectomy were more frequent in non-screen-detected breast ductal carcinoma in situ. Psychological complications, such as fatigue, anxiety, and depression, had a prevalence of 15% within our cohort. Risk of readmissions and complications was higher within the non-screen-detected group, as evidenced by an odds ratio = 6.25 (95% confidence interval = 1.95-19.99) for readmissions and an odds ratio = 2.41 (95% confidence interval = 1.95-4.86) for complications. Our findings indicate that women with breast ductal carcinoma in situ breast cancer diagnosed through population-based breast cancer screening program experience a lower risk of readmissions and complications than those diagnosed outside these programs. These findings can help aid women and health professionals make informed decisions regarding screening.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of COVID-19 on Hospital Admissions and Healthcare Quality Indicators in Non-COVID Patients, A Retrospective Study of the First COVID-19 Year in a University Hospital in Spain

  • Domingo, Laia|||0000-0003-4420-0891
  • Comas Serrano, Mercè|||0000-0003-1926-2740
  • Jansana, Anna|||0000-0001-8504-1618
  • Louro, Javier|||0000-0002-2985-3301
  • Tizón-Marcos, Helena|||0000-0001-7942-9413
  • Cos, Maria Lourdes
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Chillaron, Juan Jose|||0000-0002-8096-1703
  • Cirera, Isabel|||0000-0002-8342-6474
  • Pascual-Guardia, Sergi|||0000-0002-6567-0916
  • Sala, Maria|||0000-0002-9955-8746
  • Castells, Xavier|||0000-0002-2528-0382
Few studies have assessed the impact of the COVID-19 pandemic on non-COVID diseases and healthcare quality. We aimed to evaluate changes in rates of hospitalisations, complications, in-hospital mortality, and readmissions among patients with non-COVID diseases during a one-year period after the pandemic onset. From March 2018 to February 2021 a retrospective observational study of hospital admissions in a university hospital in Spain was conducted. Non-COVID hospitalisations admitted through the emergency department were compared between the pre-COVID period (n = 28,622) and the COVID period (n = 11,904). We assessed rate ratios (RaR), comparing the weekly number of admissions and risk ratios (RR) to examine rates of complications, in-hospital mortality, readmissions, and severity. Statistical significance was set at p < 0.05. The weekly admission rate dropped by 20.8% during the complete lockdown. We observed significant reductions in admissions related to diseases of the respiratory system and circulatory system. Admissions for endocrine and metabolic diseases increased. The complication rates increased (RR = 1.21, 95% CI: 1.05;1.4), while in-hospital mortality rates held steady during the COVID period (RR = 1.09, 95% CI: 0.98;1.2). Hospital efforts to maintain quality and safety standards despite disruptions translated into a moderate increase in complications but not in in-hospital mortality. Reduced hospitalisations for conditions requiring timely treatment may have significant public health consequences.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography

  • Román, Marta|||0000-0001-9076-8918
  • Louro, Javier|||0000-0002-2985-3301
  • Posso, Margarita|||0000-0002-5053-257X
  • Vidal, Carmen|||0000-0003-2768-2710
  • Bargalló, Xavier
  • Vázquez, Ivonne|||0000-0002-5305-1560
  • Quintana Ruiz, Maria Jesús|||0000-0002-1055-9786
  • Alcántara Souza, Rodrigo|||0000-0003-4365-5640
  • Saladié, Francina|||0000-0002-1783-4066
  • del Riego, Javier|||0000-0001-9200-3505
  • Peñalva, Lupe
  • Sala, Maria|||0000-0002-9955-8746
  • Castells, Xavier|||0000-0002-2528-0382
Assessing the long-term risk of breast cancer after diagnosis of benign breast disease by mammography is of utmost importance to design personalised screening strategies. We analysed individual-level data from 778,306 women aged 50-69 years with at least one mammographic screening participation in any of ten breast cancer screening centers in Spain from 1996 to 2015, and followed-up until 2017. We used Poisson regression to compare the rates of incident breast cancer among women with and without benign breast disease. During a median follow-up of 7.6 years, 11,708 (1.5%) women had an incident of breast cancer and 17,827 (2.3%) had a benign breast disease. The risk of breast cancer was 1.77 times higher among women with benign breast disease than among those without (95% CI: 1.61 to 1.95). The relative risk increased to 1.99 among women followed for less than four years, and remained elevated for two decades, with relative risk 1.96 (95% CI: 1.32 to 2.92) for those followed from 12 to 20 years. Benign breast disease is a long-term risk factor for breast cancer. Women with benign breast disease could benefit from closer surveillance and personalized screening strategies.